{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophreniform+Disorders&page=2", "query": { "condition": "Schizophreniform Disorders", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schizophreniform+Disorders&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:48:04.702Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00314327", "title": "Optimizing Response in Psychosis Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Schizophreniform Disorder", "Psychotic Disorder Not Otherwise Specified" ], "interventions": [ { "name": "long-acting injectable risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 1, "start_date": "2006-04", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-05-16", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 2, "location_summary": "Brooklyn, New York • Glen Oaks, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "Glen Oaks", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00314327" }, { "nct_id": "NCT01041274", "title": "DECIFER: Depression and Citalopram In First Episode Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizophreniform Disorder" ], "interventions": [ { "name": "Citalopram", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Psychoeducation", "type": "BEHAVIORAL" }, { "name": "Cognitive Behavioral Therapy (CBT)", "type": "BEHAVIORAL" }, { "name": "Functional Magnetic Resonance Imaging (fMRI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "16 Years to 40 Years" }, "enrollment_count": 95, "start_date": "2010-01", "completion_date": "2018-03-26", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041274" }, { "nct_id": "NCT00053703", "title": "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Olanzapine (enrollment closed in this treatment)", "type": "DRUG" }, { "name": "Molindone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "8 Years to 19 Years" }, "enrollment_count": 116, "start_date": "2002-02", "completion_date": "2007-05", "has_results": true, "last_update_posted_date": "2014-03-26", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 4, "location_summary": "Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Medford", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053703" }, { "nct_id": "NCT00044187", "title": "The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Psychotic Disorders", "Bipolar Disorder" ], "interventions": [ { "name": "Sibutramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 130, "start_date": "2001-04", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2006-07-19", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 16, "location_summary": "El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more", "locations": [ { "city": "El Centro", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044187" }, { "nct_id": "NCT00391261", "title": "An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Schizophreniform Disorder", "Bipolar Disorder", "Autism Spectrum Disorders" ], "interventions": [ { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cambridge Health Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 11, "start_date": "2006-07", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2010-03-25", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 1, "location_summary": "Medford, Massachusetts", "locations": [ { "city": "Medford", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00391261" }, { "nct_id": "NCT02600741", "title": "Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Caregiver psycho-education and skills training", "type": "OTHER" }, { "name": "Caregiver support available at the study site", "type": "OTHER" }, { "name": "Paliperidone palmitate", "type": "DRUG" }, { "name": "Chlorpromazine", "type": "DRUG" }, { "name": "Droperidol", "type": "DRUG" }, { "name": "Fluphenazine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Loxapine", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Pimozide", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "DRUG" }, { "name": "Thiothixene", "type": "DRUG" }, { "name": "Thioridazine", "type": "DRUG" }, { "name": "Trifluoperazine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Iloperidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 296, "start_date": "2015-07-24", "completion_date": "2018-07-05", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 34, "location_summary": "Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Lauderdale Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600741" }, { "nct_id": "NCT00492349", "title": "Varenicline Adjunctive Treatment in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Schizophreniform Disorder" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 91, "start_date": "2007-05", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2022-01-05", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 3, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492349" }, { "nct_id": "NCT03201757", "title": "Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Schizophreniform Disorder", "Bipolar I Disorder" ], "interventions": [ { "name": "ALKS 3831", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 523, "start_date": "2017-06-15", "completion_date": "2023-09-06", "has_results": true, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 49, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 40 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03201757" }, { "nct_id": "NCT01074632", "title": "Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder" ], "interventions": [ { "name": "Lurasidone HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 26, "start_date": "2009-05", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2011-09-08", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 2, "location_summary": "Glendale, California • Wichita, Kansas", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074632" }, { "nct_id": "NCT00287352", "title": "Study of Amantadine for Weight Stabilization During Olanzapine Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psychotic Disorder", "Schizophreniform Disorder", "Schizophrenia", "Schizoaffective Disorder", "Mood Disorders With Psychotic Features" ], "interventions": [ { "name": "Olanzapine, Amantadine", "type": "DRUG" }, { "name": "Olanzapine and placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2005-05", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2011-05-02", "last_synced_at": "2026-05-22T07:48:04.702Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287352" } ] }